Jubilant Pharmova Q4 Results
- BSE: 530019
- NSE: JUBLPHARMA
- ISIN: INE700A01033
- Sector: Biotechnology & Drugs
BSE
931.15
-12.10 (-1.28%)
-12.10 (-1.28%)Volume2.61 K
Updated: Thu 16 Jan, 2025 | 11:00:12
NSE
934.5-9.75 (-1.03%)
-9.75 (-1.03%)Volume36.97 K
Updated: Thu 16 Jan, 2025 | 10:49:32
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
Note: Comparison is on QoQ basis
Quarterly - Jubilant Pharmova Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 24 | Dec 23 | QoQ Comp | Mar 23 | YoY Comp |
|---|---|---|---|---|---|
| Total Revenue | 1,758.60 | 1,677.10 | 4.86% | 1,678.00 | 4.80% |
| Selling/ General/ Admin Expenses Total | 555.00 | 581.50 | -4.56% | 534.30 | 3.87% |
| Depreciation/ Amortization | 101.00 | 94.60 | 6.77% | 271.23 | -62.76% |
| Other Operating Expenses Total | 404.80 | 341.70 | 18.47% | 394.71 | 2.56% |
| Total Operating Expense | 1,757.10 | 1,553.70 | 13.09% | 1,730.01 | 1.57% |
| Operating Income | 1.50 | 123.40 | -98.78% | -52.01 | 0.00% |
| Net Income Before Taxes | -53.70 | 101.00 | 0.00% | -86.41 | -37.85% |
| Net Income | -58.60 | 66.80 | 0.00% | -97.84 | -40.11% |
| Diluted Normalized EPS | 3.25 | 4.20 | -22.71% | -6.12 | 0.00% |